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he Future Looks Bright*
ichael Salerno, MD, PHD,
hristopher M. Kramer, MD
harlottesville, Virginia
ypertrophic cardiomyopathy (HCM) is the most common
enetic cause of heart disease and the most frequent cause of
udden cardiac death (SCD) in young people (1). Deter-
ining which patients are at higher risk of the development
f adverse outcomes, particularly SCD, remains challeng-
ng. The current accepted risk factors for primary prevention
herapy with implantable cardioverter-defibrillators (ICDs)
nclude: 1) family history of HCM-related SCD; 2) unex-
lained recent syncope; 3) massive left ventricular (LV)
ypertrophy (thickness 30 mm); 4) nonsustained ventric-
lar tachycardia on 24-h Holter monitor; and 5) hypoten-
ive or attenuated blood pressure response to exercise (1).
owever, these risk factors are only supported by observa-
ional studies, and some patients without risk factors die of
CD.
See pages 867 and 875
Cardiac magnetic resonance (CMR) is emerging as a
owerful tool for the diagnosis and risk stratification in
CM. CMR is widely accepted as a gold standard method
or assessment of myocardial function as well as LV mass,
hich has been shown to be a sensitive predictor of adverse
utcomes in HCM (2). In a study comparing echocardiog-
aphy and CMR in patients with known or suspected
CM, echocardiography failed to demonstrate LV hyper-
rophy in 6% of patients, underestimated hypertrophy in the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ypertrophy 3 cm in 10% of the patients (3). The
iagnosis of apical-variant HCM can also be missed by
chocardiography, but correctly identified by CMR (4). In a
tudy of 1,299 patients with HCM, 28 demonstrated apical
neurysms by CMR, but only 16 (57%) of these were
etected by echocardiography (5). Myocardial tagging with
MR has demonstrated regional impairment in intramyo-
ardial deformation and increased myocardial torsion in
atients with HCM despite globally preserved ejection
raction in many of these patients (6,7).
As myocardial fibrosis may provide the underlying ar-
hythmogenic substrate in HCM, there has been significant
nterest in determining whether late gadolinium enhance-
ent (LGE) by CMR is in independent risk factor for
redicting SCD and other adverse outcomes. Multiple
tudies have demonstrated a high prevalence of LGE,
redominantly in a patchy, multifocal mid-wall distribution
n regions of hypertrophy (8,9). LGE has been shown to be
ssociated with nonsustained ventricular tachycardia as well
s with other risk factors for SCD (9–12). However, few
revious studies have evaluated hard end points of cardio-
ascular death, sudden cardiac death, or heart failure death.
In this issue of the Journal, Bruder et al. (13) prospectively
nrolled 243 patients with HCM who were followed for an
verage of 3 years after CMR for the primary end points of
ll-cause and cardiac mortality. The patients were predom-
nantly asymptomatic and had to have a nondilated hyper-
rophied ventricle with a maximal wall thickness 15 mm.
GE was seen in 67% of the patients, ranging from 1% to
0% of LV mass, despite the fact that nearly 75% of the
atients had no risk factors for SCD. They found that the
resence of LGE was associated with an odds ratio of 5.47
or all-cause mortality and 8.01 for cardiac mortality. This
dds ratio was greater than that associated with the presence
f 2 clinical risk factors for SCD and held up as a strong
redictor of the primary end points in multivariate analysis.
here were no events during the first 1,825 days of
ollow-up in those without LGE. Notably, 20 of the 22
atients who died during follow-up did not have previous
ymptoms, and clinical risk factors for SCD were only
resent in 3 patients who died of SCD during follow-up.
he presence of LGE was the only significant predictor of
he primary outcome besides patient age and LV mass.
owever, LGE did not reach statistical significance for
redicting SCD. This study is one of the first of its kind to
emonstrate that the presence of fibrosis/scar as detected by
GE is a significant predictor of death in HCM patients.
In a second study in this issue of the Journal, O’Hanlon et
l. (14) studied 217 HCM patients using CMR and
rospectively followed them for a mean duration of 3.1 years
or the primary composite end point, which included
ardiovascular death, unplanned cardiovascular admission,
ustained ventricular tachycardia/ventricular fibrillation, or
ppropriate ICD discharge. Although the patients’ LV
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September 7, 2010:888–9 Prognosis in HCM With Contrast-Enhanced CMRunction was similar to that of the study population of
ruder et al. (13), the mean patient age was 5 years younger,
ore than half of the subjects had New York Heart
ssociation functional class of 2, and nearly one-half had
t least 1 clinical risk factor for SCD. Similar to the study by
ruder et al., the majority of patients (63%) had LGE.
LGE was associated with a hazard ratio of 3.4 for the
rimary composite end point, and the risk increased with
he extent of LGE. The extent of LGE was also indepen-
ently predictive of worsening heart failure (unplanned
eart failure admission, progression to class III/IV conges-
ive heart failure, or heart failure death) and of the arrhyth-
ic end points (sustained ventricular tachycardia/ventricular
brillation, appropriate ICD discharge, SCD). However, in
ultivariate analysis, nonsustained ventricular tachycardia
emained an independent predictor of SCD, whereas LGE
id not. Although 83% of the major arrhythmic events
ccurred in the LGE group, the study was underpowered to
etect a significant difference for this end point. Again,
one of the other standard clinical risk factors were predic-
ive of SCD events.
The primary end point was largely driven by unplanned
ardiovascular admissions (29 of the 40 primary end points),
nd in their cohort, the individual end points of cardiovas-
ular death and ventricular tachycardia/ventricular fibrilla-
ion and SCD were not independently predicted by LGE.
owever, this is likely due to the relatively small number of
hese events (9, 9, and 2, respectively). Longer follow-up in
arger cohorts will be necessary to have adequate numbers of
vents to achieve statistical significance.
In one of the few previous studies looking at outcomes
ith LGE in HCM, Maron et al. (15) studied 202 patients
mean age 42 years) over an average of 1.9 years for the
dverse cardiovascular event rate (including progressive
eart failure, SCD, and appropriate ICD shock) and failed
o show a difference in the annualized event rate between
atients with (5.5%) and without (3.3%) LGE. However,
his negative result could have been due to the duration of
ollow-up or the younger age of their cohort. More recently,
ubinshtein et al. (16) followed 424 patients with HCM
mean age 55 years) over 3.6 years and demonstrated a
trong association of LGE with SCD and appropriate ICD
ischarges even after controlling for other variables.
Thus, the studies in this issue of the Journal add to the
rowing body of literature suggesting that LGE should be
onsidered as an independent predictor of adverse cardiac
utcomes. However, a large, prospectively designed study is
till needed to definitively establish LGE as a predictor of
CD and cardiac death in HCM. Due to the relatively small
umber of patients with HCM at any 1 center, a multi-
enter collaborative clinical trial would be the best way to
efinitively answer this question. Randomizing HCM pa-
ients with LGE without standard clinical indications for
CD therapy or no therapy could be one way of designing
uch a study. Understanding how well today’s accepted slinical risk factors predict ICD discharge with the use of a
egistry would also help in this regard. The time has come
or LGE by CMR to be examined carefully as a potential
isk marker in this deadly disease.
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ramer, Departments of Medicine and Radiology, University of
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